In vitro potency tests: challenges encountered during method development.
Vaccines play a key role in the control of viral diseases both in humans and in animals. In order to ensure the quality and consistency of vaccines they are extensively tested, including potency control of individual batches. In the case of vaccines against rabies the most widely used test for batch potency control is the National Institutes of Health (NIH) test. The NIH test is performed in mice leading to the consumption of thousands of animals every year. Protection against rabies after vaccination is associated with neutralizing antibodies directed against the viral glycoprotein (G). Therefore the amount of G-protein in vaccine preparations is an important parameter with regard to potency. Additionally the structural integrity of virus particles in vaccine preparations may be crucial for their immunogenicity. The objective of our work is the development of in vitro methods to determine the potency of vaccines against rabies. The result of this ongoing project shall be an assay panel including measurement of the antigenic content as well as parameters of antigen quality in a vaccine preparation allowing a precise prediction of the potency of rabies vaccines without using animal experiments.
Institute of Virology, Faculty of Veterinary Medicine, Justus-Liebig, Universität, Giessen, Germany.
C L
CL
Yomayuza
H-J
HJ
Thiel
M
M
König
D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D051379:Mice; D008854:Microscopy, Electron; D019590:Nucleocapsid Proteins / Q000276:immunology; D011818:Rabies / Q000276:immunology* / Q000517:prevention & control; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology* / Q000648:ultrastructure; D014611:Vaccination / Q000379:methods*
D000956:Antigens, Viral; D019590:Nucleocapsid Proteins; D011819:Rabies Vaccines; C099601:nucleocapsid protein, Rabies virus